FindTrial
Sign In

Antiarrhythmic drugs

DRUG5 trials

Sponsors

Biosense Webster EMEA, National Institute of Cardiology, Warsaw, Poland, Medtronic Cardiac Ablation Solutions, University of Sao Paulo General Hospital, Assiut University

Conditions

Antiarrhythmic Drug Adverse ReactionArrhythmias VentricularAtrial FibrillationHypertrophic CardiomyopathySymptomatic Paroxysmal Atrial Fibrillation Without Clinically Significant Heart Diseases

Phase 3

Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy
CompletedNCT00821353
National Institute of Cardiology, Warsaw, PolandAtrial Fibrillation, Hypertrophic Cardiomyopathy
Start: 2009-01-31End: 2012-06-30Target: 90Updated: 2013-02-05

Phase 4

CACAF2 Study: Catheter Ablation for Cure of Atrial Fibrillation
TerminatedNCT00227344
Biosense Webster EMEAAtrial Fibrillation
Start: 2004-12-31End: 2009-05-31Updated: 2025-02-04
Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation
CompletedNCT01803438
Medtronic Cardiac Ablation SolutionsSymptomatic Paroxysmal Atrial Fibrillation Without Clinically Significant Heart Diseases
Start: 2014-06-30End: 2020-01-20Updated: 2025-02-13
PROSPECTIVE ANALYSIS BETWEEN AMIODARONE Versus LIDOCAINE IN SVT
NCT03299517
University of Sao Paulo General HospitalArrhythmias Ventricular
Start: 2017-08-02End: 2022-08-02Target: 80Updated: 2018-10-24

Unknown Phase

The Use of Antiarrhythmic Drugs in Pediatrics
Not yet recruitingNCT06272357
Assiut UniversityAntiarrhythmic Drug Adverse Reaction
Start: 2024-04-01End: 2025-03-31Target: 158Updated: 2024-02-22

Related Papers

The Cost-Effectiveness of First-Line Cryoablation vs First-Line Antiarrhythmic Drugs in Canadian Patients With Paroxysmal Atrial Fibrillation.
2023-11-236 citations
An economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a German healthcare service payer perspective
European Heart Journal2023-11-012 citations
An economic evaluation of first-line cryoballoon ablation vs antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a U.S. Medicare perspective
Heart Rhythm O22023-07-2713 citations
Initial rhythm control with cryoballoon ablation vs drug therapy: Impact on quality of life and symptoms
American Heart Journal2021-09-0813 citations
Impact of initial rhythm control with cryoballoon ablation versus drug therapy on atrial fibrillation recurrence and quality of life: results from the Cryo-FIRST study
EP Europace2021-05-01
Abstract 13915: Cryoballoon Catheter Ablation versus Antiarrhythmic Drug as a First-Line Therapy for Patients With Paroxysmal Atrial Fibrillation: Results of the Cryo-FIRST Study
Circulation2020-11-173 citations
Abstract 13916: Quality of Life Measured in First-line Therapy for Paroxysmal Atrial Fibrillation: A Comparison Between Cryoballoon Catheter Ablation versus Antiarrhythmic Drug Therapy
Circulation2020-11-171 citations